Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2025-05-06 Interim / Quarterly Rep…
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Informe de negocio del primer trimestre de 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INFORME Q1 2025 FAES FARMA' and contains detailed financial statements, business performance analysis, and management commentary for the first quarter of 2025. It includes tables for income statements, revenue breakdowns by business area, and comparisons with the previous year. While it is presented in a slide-deck format, it provides substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-06 Spanish
Faes Farma anuncia la celebración de un webcast para presentar los resultados del primer trimestre de 2025
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1301 characters) addressed to the 'COMISIÓN NACIONAL DEL MERCADO DE VALORES' (CNMV, the Spanish securities market regulator). The content explicitly announces a 'Webcast para analistas e inversores: Presentación de resultados del primer trimestre 2025' (Webcast for analysts and investors: Presentation of first-quarter 2025 results) and provides registration details and access information for the recording. This is not the actual earnings report (ER) or the detailed management discussion (MDA), but rather an announcement about the upcoming event where the results will be discussed. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or discussion of a report falls under Report Publication Announcement (RPA).
2025-04-29 Spanish
Presentación Capital Markets Day 2025
Investor Presentation Classification · 98% confidence The document text is extensive (nearly 40,000 characters) and structured like a detailed presentation, featuring an 'AGENDA', slides with titles like 'Sólidos fundamentos: 2014-2024', 'Plan Estratégico 2025-2030: Transformando el futuro', and detailed strategic pillars, financial projections (CAGR, EBITDA), and organizational charts. This format strongly indicates an Investor Presentation (IP) or a similar strategic update document, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). It is too detailed to be an RPA or RNS, and it is not a transcript (CT) or a formal annual/interim report (10-K/IR).
2025-04-22 Spanish
La Sociedad comunica que hoy celebrará su Capital Markets Day para presentar el nuevo Plan Estratégico del Grupo.
Investor Presentation Classification · 99% confidence The document is a short communication addressed to the 'COMISIÓN NACIONAL DEL MERCADO DE VALORES' (CNMV, the Spanish securities market regulator) under Article 227, labeled as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content announces that the company, Faes Farma, will hold its 'Capital Markets Day' today to present the new Strategic Plan. This is an announcement about an upcoming investor event where strategy and growth objectives will be detailed. This fits best under Investor Presentation (IP) as it relates to presenting strategy and future plans to investors, although the document itself is the announcement of the event, not the presentation slides. Given the short length and the nature of announcing a strategic presentation event, it is closely related to investor communication materials. However, since the document is announcing the event where the presentation will happen, and it is a formal regulatory disclosure, it is a specific type of investor communication. The closest fit among the provided codes for an announcement detailing an upcoming strategic presentation event is Investor Presentation (IP), as it directly relates to the content being presented. If the document were the presentation itself, IP would be certain. As an announcement of the event, it is a precursor. Given the options, IP is the most relevant category for strategic investor updates, even if this specific text is the announcement notice.
2025-04-22 Spanish
Faes Farma S.A. ha suscrito un contrato para la adquisición de Laboratorios Edol Productos Farmacêuticos, S.A
M&A Activity Classification · 99% confidence The document is a formal communication from FAES FARMA, S.A. to the COMISION NACIONAL DEL MERCADO DE VALORES (CNMV, the Spanish securities market regulator). The header explicitly labels the content as "INFORMACIÓN PRIVILEGIADA" (Inside Information/Privileged Information). The core content details a significant corporate action: the signing of a contract to acquire 100% of the shares of Laboratorios Edol for 75 million euros. This type of announcement, concerning a major transaction like an acquisition or takeover bid, falls under the category of M&A Activity (TAR). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about a strategic transaction.
2025-03-25 Spanish
Informe de negocio y resultados 2024
Management Reports Classification · 95% confidence The document is a comprehensive financial summary titled 'Informe 2024' (Report 2024) published in February 2025. It contains detailed financial tables, including income statements, EBITDA, net profit, and business segment performance (Farma, Nutrición y Salud Animal) for the full fiscal year 2024. It provides a management-level analysis of business trends, geographic performance, and operational highlights. Since it contains substantive financial data and analysis for the full year but is presented as a summary report rather than the formal, audited 10-K/Annual Report filing, it is best classified as a Management Report (MDA) or an Interim/Quarterly Report (IR) equivalent for the full year. Given the detailed management commentary on financial results, 'MDA' is the most accurate fit. FY 2024
2025-02-28 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.